Blood tests could make kidney cancer drugs safer and more effective

NCT ID NCT04659343

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks drug levels in the blood of 200 people with advanced kidney cancer to see if monitoring can improve how well the drugs work and reduce side effects. Researchers will also look at how the body's immune system and genes affect treatment. The goal is to find better ways to personalize care for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG MECHANISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Oncology, Aarhus University Hospital

    RECRUITING

    Aarhus, Danmark, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.